Glenmark Pharmaceuticals has received approval from the Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials for the efficacy of a combination of the antiviral drugs Favipiravir and Umifenovir as a potential treatment strategy for Covid-19. The new combination clinical trial will be called FAITH – (FA vipiravir plus Um I fenovir (efficacy and safety) Trial in Indian Hospital setting .